A-STIN
A-STIN (SCAI Therapeutics, Inc.) is a South Korean biotechnology company developing pharmaceutical and cosmetic innovations through its proprietary MOASIS® and NDT molecule-based technology platforms, serving the drug development and cosmetics industries from Daejeon.
- Company typePrivate
- Founded2013
- HeadquartersDaejeon, South Korea
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
A-STIN firmographics
Firmographics- Name
- A-STIN
- Legal name
- SCAI Therapeutics, Inc.
- Website
- https://a-stin.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- A-STIN (SCAI Therapeutics, Inc.) is a South Korean biotechnology company developing pharmaceutical and cosmetic innovations through its proprietary MOASIS® and NDT molecule-based technology platforms, serving the drug development and cosmetics industries from Daejeon.
- Ownership category
- akta.pro rank
Where A-STIN is headquartered
LocationHeadquarters
- HQ city
- Daejeon
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
A-STIN business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
A-STIN product offering
Product offeringCore offering
A-STIN is a technology development company that innovates and evolves cosmetic material technology, operating through proprietary molecule-based platforms (MOASIS® and NDT) that underpin both pharmaceutical drug development and commercial cosmetic products. The company develops and supplies innovative cosmetic materials and therapeutic candidates derived from these platforms to buyers in the pharmaceutical and cosmetics industries.
Differentiator
Problem solved
Functional benefit
Products and services
- Commercial Cosmetic & Therapeutic Products Commercial cosmetic materials and therapeutic products developed from the company's proprietary molecule-based platforms, supplied to pharmaceutical and cosmetic industry buyers.
- Drug Development Pipeline Pipeline of therapeutic candidates in research and development that the company is advancing toward commercialization using its proprietary platforms.
Companies that use A-STIN
Customer profileSegments1 record
Ideal customer profiles1 record
A-STIN technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
A-STIN competitors and assessment
Company assessmentDirect peers
- Symrise: Global supplier of cosmetic ingredients, fragrances, and functional actives with proprietary platform technologies serving personal-care and pharma customers. Directly comparable to SCAI's positioning at the intersection of cosmetic and pharmaceutical molecular innovation.
- Kolmar Korea: Major Korean cosmetics and health-functional-food manufacturer with strong proprietary R&D and a pipeline-to-product model. Highly comparable to SCAI's dual focus on innovation platforms and finished cosmetic/therapeutic products.
- Croda International: Global specialty ingredients company supplying personal-care, pharmaceutical, and life-sciences markets with proprietary actives and delivery technologies. Comparable to SCAI as a platform-based supplier of innovative molecular technologies into both cosmetics and pharma.
- Cosmax: Korea's largest cosmetics ODM, developing proprietary formulation and ingredient technologies for global beauty brands. Comparable to SCAI as a Korean platform company commercializing proprietary cosmetic/ingredient innovation across multiple end markets.
- Hugel: Korean biotech specializing in aesthetics and therapeutic biologics built on proprietary platform technology. Directly comparable to SCAI as a small/mid Korean platform company pursuing both therapeutic and aesthetic applications.
Others
- Evonik Industries: Global specialty chemicals company with dedicated personal-care and pharma delivery/excipient businesses built on proprietary molecular platforms. Comparable to SCAI as a platform-driven supplier to cosmetics and pharma, but at much broader scale.
Broad incumbents
- LG Household & Health Care: Major Korean consumer-health and beauty company with proprietary R&D and active ingredients across cosmetics, OTC, and pharma. Comparable to SCAI as a Korean player operating at the pharma/cosmetics interface, though at substantially larger scale.
- Amorepacific: Korea's leading cosmetics conglomerate with deep proprietary R&D across skincare, makeup, and ingredients. Comparable to SCAI as a Korean beauty/cosmetics innovator, though operating at much larger scale across global markets.
- BASF (Personal Care / Care Chemicals): Global chemical incumbent with a large Personal Care and pharma excipients business built on proprietary ingredient and formulation platforms. Comparable to SCAI as a platform-based innovator supplying cosmetic and pharmaceutical end markets, but vastly larger and more diversified.
Emerging players
- Daewoong Pharmaceutical: Korean pharmaceutical company with proprietary drug-delivery and formulation platforms and a growing aesthetics/cosmetic adjacency. Comparable to SCAI's strategy of leveraging molecular innovation across pharma and cosmetic/therapeutic applications.
Market position
Customer concentration
A-STIN financial estimates
Financial estimateRevenue estimate
Valuation estimate
A-STIN leadership team
Management profileNumber of profiles
A-STIN funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
A-STIN M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about A-STIN
What does A-STIN do?
A-STIN is a technology development company that innovates and evolves cosmetic material technology, operating through proprietary molecule-based platforms (MOASIS® and NDT) that underpin both pharmaceutical drug development and commercial cosmetic products. The company develops and supplies innovative cosmetic materials and therapeutic candidates derived from these platforms to buyers in the pharmaceutical and cosmetics industries.
Is A-STIN a public or private company?
A-STIN is a private company. It is classified as venture growth investor backed and is currently operating.
When was A-STIN founded?
A-STIN was founded in 2013. It employs 1 to 10 people.
Where is A-STIN based?
A-STIN is headquartered in Daejeon, South Korea, in the Asia region.
Who are A-STIN's main competitors?
Direct peers on record are Symrise, Kolmar Korea, Croda International, Cosmax and Hugel. Evonik Industries is listed as an others. Broad incumbents are LG Household & Health Care, Amorepacific and BASF (Personal Care / Care Chemicals). Daewoong Pharmaceutical is listed as an emerging player.
Does A-STIN have an API?
No public API is recorded for A-STIN.